Featured Bioprocessing Editorial

  1. A Study In Optimizing Late-Stage Processes With QbD, DoE 9/26/2025

    Nobody wants to redesign analytical process profiles when a market approval is within reach, but what about when a last-lap QbD exercise could bring real benefit?

  2. Automation In The Lab: Lessons From Successes And Setbacks 9/24/2025

    Real-world examples show that, in some labs, manual screenings disappeared altogether, replaced by automated runs that now cover entire departments.

  3. Defining Strong Program Management In CDMO Partnerships 9/23/2025

    This first article of a planned three-part series discusses the pitfalls that program managers help sponsor companies avoid, how program managers accelerate timelines or reduce risk, and more.

  4. CGT Success Starts With The First Mile 9/23/2025

    The so-called "last mile" in cell therapy gets a lot of attention. What about the first mile, the journey cells take between the donor and the manufacturing site?

  5. Can CHO Bioreactors Be Used For Plant-Based Protein Production? 9/22/2025

    The moss Physcomitrium patens is especially good at producing glycoproteins. Established technology and prior knowledge are helping one company develop new therapies with it.

  6. How To Grow CHO Cells Without Cysteine, Tyrosine Feeds 9/19/2025

    Researchers at Pfizer are developing a cell line that synthesizes these amino acids autonomously, which could reduce costs and increase stability.

  7. Making The Leap To Smart Bioprocessing 9/19/2025

    A European consortium achieved greater T cell expansion compared to baseline conditions using real-time process monitoring and control.

  8. Unlocking Method Insights For Novel Engineered AAV Capsids 9/18/2025

    Microfluidic platforms, such as labchip, are widely used for assessing wild type capsids. Now, engineered capsids are challenging these established workflows.

  9. Why FDA's Tough Talk On Foreign Inspections Is More Bark, Less Bite 9/18/2025

    FDA Commissioner Marty Makary has promised to end the so-called "double standard" of announced overseas inspections. Does the agency have the resources?

  10. Manufacturing Interleukin-2 For In Vivo Use: Key Considerations 9/16/2025

    Interleukins help optimize therapeutic outcomes in cancer immunotherapy and regenerative medicine. Manufacturing success requires stringent control over production, formulation, and stability to ensure safety and efficacy.